尋常性ざ瘡（Acne Vulgaris）：グローバル製薬市場機会分析と予測...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 9
1.1 List of Tables 13
1.2 List of Figures 15
2 Introduction 16
2.1 Catalyst 16
2.2 Related Reports 17
3 Disease Overview 18
3.1 Etiology and Pathophysiology 18
3.2 Prognosis 22
3.3 Quality of Life 22
3.4 Symptoms 23
4 Epidemiology 25
4.1 Risk Factors and Comorbidities 26
4.1.1 A family history of acne increases the risk of acne by four times 26
4.1.2 Diet is the most common aggravating factor of acne 27
4.1.3 The relationship between smoking and acne is unclear 28
4.1.4 Depression and anxiety are common comorbidities in acne patients 29
4.2 Global Trends 30
4.2.1 US 31
4.2.2 5EU 32
4.3 Forecast Methodology 34
4.3.1 Sources Used 35
4.3.2 Sources Not Used 37
4.4 Forecast Assumptions and Methods 38
4.4.1 US 38
4.4.2 France 39
4.4.3 Germany 39
4.4.4 Italy and Spain 40
4.4.5 UK 40
4.5 Epidemiology Forecast for Acne (2012-2022) 41
4.5.1 Total Prevalent Cases of Acne Vulgaris 41
4.5.2 Age-Specific Total Prevalent Cases of Acne Vulgaris 43
4.5.3 Sex-Specific Total Prevalent Cases of Acne Vulgaris 44
4.5.4 Age-Standardized Total Prevalence of Acne Vulgaris 46
4.5.5 Total Prevalent Cases of Acne Vulgaris by Severity 47
4.6 Discussion 49
4.6.1 Conclusions on Epidemiological Trends 49
4.6.2 Limitations of the Analysis 50
4.6.3 Strengths of the Analysis 51
5 Current Treatment Options 53
5.1 Overview 53
5.2 Product Profiles – Major Brands 56
5.2.1 Tretinoin (numerous brand and generic names) 56
5.2.2 Isotretinoin 60
5.2.3 Adapalene (numerous generic names) 63
5.2.4 Benzoyl Peroxide (numerous generic names) 66
5.2.5 Azelaic Acid (numerous generic names) 70
5.2.6 Hormonal Therapy (numerous brand and generic names) 73
5.2.7 Epiduo (adapalene and benzoyl peroxide) 76
5.2.8 Tretinoin and Clindamycin Phosphate (numerous brand names) 81
5.2.9 Benzoyl Peroxide and Clindamycin Phosphate (numerous brand and generic names) 84
5.2.10 Benzoyl Peroxide and Erythromycin (numerous brand and generic names) 87
5.2.11 Isotretinoin and Erythromycin (numerous brand and generic names) 90
5.2.12 Zineryt (erythromycin and zinc acetate) 93
6 Unmet Needs Assessment and Opportunity Analysis 96
6.1 Overview 96
6.2 Unmet Needs Analysis 97
6.2.1 Inadequate Investment in Innovative Drugs 97
6.2.2 Improved Compliance 98
6.2.3 Cost-Prohibitive Products 99
6.2.4 Increased Patient and Caregiver Awareness 100
6.2.5 Non-Teratogenic Treatment Options for Female Acne Patients of Childbearing Age 100
6.3 Opportunity Analysis 101
6.3.1 Investment in Novel Systemic Compounds 101
6.3.2 Affordable and Accessible Combination Treatment Options 101
6.3.3 Holistic Management of Acne Patients 101
6.3.4 Exploring Photodynamic Therapy as a Potential Treatment for Acne 103
7 R&D Strategies 105
7.1 Overview – Lifecycle Management Strategies 105
7.1.1 Reformulation Strategies 105
7.1.2 M&A in the Dermatology Market 107
7.1.3 Label Expansion into Pediatric Population 107
7.2 Clinical Trial Design 108
7.2.1 Current Clinical Trial Design 108
7.2.2 Limitations of Current Clinical Trial Design 109
7.2.3 Future Outlook in Acne Clinical Trial Design 110
8 Pipeline Assessment 113
8.1 Overview 113
8.2 Promising Drugs in Clinical Development 114
8.2.1 ASC-J9 114
8.2.2 Visonac (methyl aminolevulinate) 120
8.3 Innovative Early-Stage Approaches 127
8.3.1 Anti-Inflammatory Drugs 128
8.3.2 Vaccine Development 129
8.3.3 Neuropeptides 131
8.3.4 Phages 131
9 Pipeline Valuation Analysis 132
9.1 Clinical Benchmark of Key Pipeline Drugs 132
9.2 Commercial Benchmark of Key Pipeline Drugs 134
9.3 Competitive Assessment 136
9.4 Top-Line Five-Year Forecast 138
9.4.1 US 142
9.4.2 5EU 143
10 Appendix 145
10.1 Bibliography 145
10.2 Abbreviations 159
10.3 Methodology 162
10.4 Forecasting Methodology 162
10.4.1 Diagnosed Acne Vulgaris Patients 162
10.4.2 Percent Drug-Treated Patients 163
10.4.3 Drugs Included in Each Therapeutic Class 163
10.4.4 Launch and Patent Expiry Dates 164
10.4.5 General Pricing Assumptions 164
10.4.6 Individual Drug Assumptions 165
10.4.7 Pricing of Pipeline Agents 171
10.5 Physicians and Specialists Included in this Study 172
10.6 About the Authors 173
10.6.1 Author 173
10.6.2 Author/Reviewer 173
10.6.3 Reviewer 174
10.6.4 Epidemiologist 174
10.6.5 Global Head of Healthcare 175
10.7 About GlobalData 176
10.8 Disclaimer 176